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Introduction
Colorectal cancer (CRC) is considered the third most 
common cancer in men, and second in women worldwide (1). 
Surgical treatment is the most important approach in these 
patients, and in 80% of them, surgery can be performed. In 
locally advanced tumors, surgery must be supplemented with 
chemotherapy. Nowadays there is a progressive increase of 
synchronous metastatic CRC, and approximately 20% of 
patients present distant metastases at the time of diagnosis (2). 
In stage IV CRC, systemic chemotherapy is the cornerstone 
of therapy, taking into account that if a good response is 
obtained, surgical treatment could be performed. Between 
40% and 70% of these patients will present a good response 
to palliative systemic treatment. The 5-year survival rate at 
stage IV is approximately 11.7% (3,4). About one half of 
non-metastatic CRC will develop liver metastases during 
follow-up. If metastases are restricted to liver or lung, and 
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a complete excision of them can be achieved, these patients 
can benefit from curative surgery, with a significant benefit in 
overall survival (OS) (5,6).
There is a recent trend to treat preoperatively locally 
advanced colon cancer in order to let patients benefit from 
neoadjuvant chemotherapy, achieve downstaging, and 
diminish the recurrence rate (7,8). In this scenario it would 
be interesting to determine the surgical morbidity rates 
of colon surgery after neoadjuvant chemotherapy in other 
group of patients.
This study assesses the surgical complications of primary 
tumor resection in stage IV colon cancer patients—excluding 
rectal cancer—treated with preoperative chemotherapy. 
The physiological and operative severity score for the 
enumeration of mortality and morbidity (POSSUM) and 
the Portsmouth-POSSUM (P-POSSUM)—a modification 
of the POSSUM—scoring systems allow to compare the 
outcomes of surgical procedures according different degrees 
of complexity (9-11). They offer a way of estimating 
the probability of morbidity and mortality taking into 
account the magnitude of surgery and the preoperative 
physiological status of the patients. These scores are a good 
tool to evaluate if neaodjuvant therapy increases or not the 
expected complication rate.
Material and methods
This retrospective study included consecutive clinical stage 
IV colon adenocarcinoma patients who underwent primary 
tumour surgery after receiving preoperative chemotherapy at 
our center, between July 1st, 2001 and September 30th, 2010.
Study protocol, treatment scheme and follow-up
Init ia l  c l inical  s taging was  performed through a 
colonoscopy with tumor biopsies, tumor markers and 
computed tomography (CT). In some cases diagnosis was 
supplemented with positron emission tomography (PET) 
or liver magnetic resonance image (MRI). Exclusion criteria 
included tumors within 15 cm of the anal verge, judged 
by sigmoidoscopy, or those below the level of the sacral 
promontory, judged by imaging methods. Patients with 
bleeding or obstruction underwent surgical treatment and 
they were not included in this study. Patients received 
different schemes of preoperative chemotherapy based on 
FOLFIRI (12), XELOXIRI (13) or XELOX plus cetuximab 
regimen (14). 
Patients were re-staged at the end of chemotherapy 
and before surgery to value tumor response and 
determine surgical treatment feasibility. After completing 
chemotherapy, patients were subjected to radical excision 
of the primary tumor after four weeks from the end of 
chemotherapy. Occasionally, liver surgery was performed 
during the same surgical procedure. 
Postoperative complications were defined as any clinical 
condition that required prolonged hospital stay or any 
deviation from the normal postoperative course. Operative 
mortality was stated as death within the first 30 days 
postoperative or during hospital admission after the surgical 
procedure. It was tried to minimize risk of infection, so 
maintenance of venous accesses or bladder catheters was 
valued on a daily basis. Furthermore, antithrombotic 
prophylaxis was accomplished by using low molecular 
weight heparin, pneumatic compression boots during the 
operation and compression stockings. Early ambulation 
and respiratory physiotherapy was encouraged. Nasogastric 
tube and drainage systems were reserved for selected cases, 
trying to restrict their usage.
Statistical methods
Patient data were obtained from the medical records. The 
incidence of complications was calculated for the entire 
population. Values are expressed as medians with range in 
quantitative variables, or as percentages of the group of 
origin in categorical variables. All statistical analyses were 
performed using SPSS software (version 15.0, SPSS Inc., 
Chicago, IL, USA).
Results
Between July 1, 2001 and September 30, 2010, 67 patients 
went through surgical excision of the primary tumour after 
receiving chemotherapy for stage IV colon cancer.
Table 1 shows baseline patient characteristics. All patients 
were affected with liver metastasis, with 76.1% (n=51) of 
them affecting both lobes. Furthermore, 29.8% (n=20) 
of them had metastasis in additional organs. The mean 
carcinoembryonic antigen (CEA) at the moment of initial 
diagnosis was 107.5 ng/mL. 
Twenty eight patients (41.8%) received XELOXIRI, 
24 (35.8%) XELOX plus cetuximab and 15 (22.4%) 
FOLFIRI. In 58.2% of patients, four neoadjuvant cycles 
were administrated. Global median number of administered 
cycles was 4 [3-6] (Table 2). Eighteen patients (26.8%) 
reported some side effects to the chemotherapy, which did 
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not contraindicate surgery. The most frequent complication 
was diarrhea, in six patients followed by neutropenia, in 
five patients. There was not any differences in complication 
rates between the three chemotherapy lines administered 
(P=0.65). After chemotherapy administration and before 
surgery, haemoglobin, leukocytes and platelets mean levels 
were 11.7×1012/L (8.6-15.3), 5.6×109/L (2.3-13.7) and 
225×109/L [72-576] respectively. Median time between 
the start of chemotherapy and surgery was 107 days, and 
between the end of chemotherapy and surgery was 29 days. 
After neoadjuvant treatment, 53 patients (79.1%) achieved 
hepatic partial response, and 14 (20.9%) stability of the 
disease.
All patients underwent colon surgery and within 
those, eight patients (11.9%) underwent liver surgery 
simultaneously. Twenty-eight patients (41.8%), underwent 
liver surgery as a second procedure, and three patients 
(4.5%) underwent liver resection as the first procedure. 
Twenty-eight patients (41.8%) only underwent primary 
tumour surgery. In twelve cases (17.9%) a complementary 
surgery was conducted. Forty-nine sigmoidectomies/left-
hemicolectomies, 14 right hemicolectomies, 2 transverse 
colon resections and 2 Hartmann operations were performed. 
In 23 patients (34.3%) a laparoscopic approach was elected. 
Pathologic characteristics of primary tumour are summarized 
in Table 3. Seven patients required blood transfusion during 
their hospital admission: one packed red blood cells (PRBC) 
on three patients and two PRBC on four patients. Median 
surgical time was 203 [75-469] minutes and median hospital 
admission was a total of 8 [3-29] days. 
In Table 4 the complications reported in the first 30 days 
after surgery are shown. The complication rate was 16.4%, 
Table 1 Baseline patient characteristics
N [%]
Age* 60 [28-83]
Sex
Female 34 [50.7]
Male 33 [49.3]
ASA
II 23 [34.3]
III 42 [62.7]
IV 2 [2.9]
BMI* 25.1 [15.2-39]
Comorbidity 37 [55.2]
Location
Descending-sigmoid 51 [76.1]
Ascending 14 [20.9]
Transverse 2 [2.9]
Obstructing 15 [22.4]
Metastatized organ
Liver 67 [100]
Lung 12 [17.9]
Retroperitoneum 3 [4.5]
Mediastinum 2 [2.9]
Peritoneum 2 [2.9]
Adrenal gland 1 [1.5]
Hepatic metastasis distribution
Unilobar 16 [23.9 ]
Bilobar 51 [76.1]
Number of hepatic metastases* 5 [1-20]
*, median (range).
Table 2 Completion chemotherapy rate
Completion rate (%) Cause for stopping
XELOXIRI 85.7 Obstruction, diarrhea
XELOX + 
cetuximab
87.5 Obstruction, neutropenia
FOLFIRI 80 Mucositis, neutropenia
Table 3 Pathologic characteristics of primary tumor
N [%]
Lymphovascular invasion
Yes 33 [49.3]
No 64 [50.7]
Perineural invasion
Yes 27 [40.3]
No 40 [59.7]
Negative margin 67 [100]
y-T stage
T1 6 [9]
T2 8 [11.9]
T3 49 [73.1]
T4 3 [4.5]
y-N stage
N0 25 [37.3]
N1 27 [40.3]
N2 15 [22.4]
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and no patient presented more than one complication. The 
morbidity predicted by POSSUM was 58.3%. There was 
not perioperative mortality, despite mortality prediction for 
P-POSSUM being 5.07%. No differences were observed 
between the chemotherapy regimen (P=0.72) or the kind of 
the surgery—simple or combined (P=0.58). After a median 
follow-up period of 25 months, the median OS was 31 (95% 
CI: 23-39) months. There were no cases of local relapse. 
Discussion
This study aims to analyze the surgical morbidity secondaty 
to primary tumor resection after neoadjuvant chemotherapy, 
in a group of patients diagnosed with stage IV colon 
adenocarcinoma. The three most important chemotherapy 
regimens used in our hospital during the nine-year study-
period were included: FOLFIRI, XELOXIRI, and XELOX 
together with cetuximab.
We included all complications that patients presented 
during chemotherapy treatment, hence global morbidity 
rate being 26.8%. It was not necessary to contraindicate 
surgery in any of the eighteen patients who presented 
complications. Blood levels of haemoglobin, leukocytes 
and platelets were analyzed and all of them were within the 
accepted range in order to perform a safe surgery. 
Global complications that appeared after primary tumor 
resection were assessed, including cases where another 
surgical intervention was simultaneously performed. Five 
surgical and six clinical complications were observed. The 
complication global rate was 16.4%, which is comparable 
to another reported series (15-17) and much lower than the 
morbidity prediction for this group of patients (16.4% vs. 
58.3%). Different speciality-specific POSSUM models have 
been developed, like O-POSSUM (18) or CR-POSSUM (19). 
POSSUM and P-POSSUM have been considered a good 
predictor of surgical complications (20) although some 
studies suggest an overprediction for colon cancer surgery 
with these scores (21).
No cases of surgical conversion from laparoscopic to 
open approach were observed and the reoperation rate 
was little lower than what has been described by other 
authors: 2.9% vs. 3.8-5.8% (15,22). These two cases of 
reoperation were secondary to an anastomotic leakage. One 
should mention the low blood transfusion requirement. 
The hospital admission period is within the same range as 
other colorectal surgery series. It is known that the previous 
comorbidity is a risk factor of surgical complications and 
hospital stay (23). Fifty five percent of our patients had 
some important copathology. No cases of perioperative 
mortality were registered. 
If patients with unresectable metastatic colon cancer 
should undergo primary tumor resection still remains 
controversial. Some authors prefer primary chemotherapy 
(24-26), while others think that primary colectomy 
improves OS compared with only chemotherapy (27-29).
In stage IV CRC patients who complete all treatment 
steps, classical (primary tumour resection, liver metastases-
directed chemotherapy followed by hepatic resection) and 
reversed (liver metastases-directed chemotherapy, hepatic 
resection and then, primary tumour resection) sequential 
managements have been associated with similar survival 
rates (30).
We can find some limitations in this study, such as 
the unicentric and retrospective character and the use of 
different chemotherapy regimens before surgery. On the 
other hand, this is a selected group of patients that were 
able to achieve the surgical treatment after chemotherapy.
Although chemotherapy treatment was administrated 
before surgery, our results are within the accepted 
postoperative complication limits of colorectal surgery. 
Used antithrombotic prophylaxis avoided cases of deep 
venous thrombosis or pulmonary thromboembolism, and 
respiratory physiotherapy avoided frequent pulmonary 
complications, such as pneumonia or respiratory failure 
in this study. We could confirm that chemotherapy 
does not indicate surgery contraindication nor increases 
postoperative morbi-mortality by a significant amount. 
This fact, showing the safety of preoperative chemotherapy, 
could be another reason to believe that neoadjuvant therapy 
could have a role to play in patients with locally advanced 
colon cancer. 
Table 4 Perioperative complications
Complication N (%)
Anastomotic leakage 2 (2.9)
Ileus 2 (2.9)
Fever 2 (2.9)
Ascites 1 (1.5)
Purulent drainage 1 (1.5)
Central venous access infection 1 (1.5)
Urinary tract infection 1 (1.5)
Lower gastrointestinal bleeding 1 (1.5)
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Conclusions
Neoadjuvant chemotherapy as a systemic treatment for 
stage IV colon cancer does not associate with a high 
postoperative complication risk.
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